Reviews Follitropin Beta


No reviews yet.

Follistim AQ Drug Description
Follistim® AQ
(follitropin beta) Injection
FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ »




Follistim® AQ (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results ina highly purified preparation with a consistent
hFSH isoform profile and high specific activity1. The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.
The amino acid sequence and tertiary structure of the product are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physio-chemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ is presented as a sterile aqueous solution intended for SUBCUTANEOUS
or INTRAMUSCULAR administration. Each single-use vial of Follistim® AQ contains
the following per 0.5 mL: 75 IU or 150 IU of FSH activity; 25 mg sucrose, NF;
7.35 mg sodium citrate (dihydrate), USP; 0.25 mg L-methionine, USP; 0.1 mg polysorbate
20, NF; and water for injection, USP. Hydrochloric acid, NF and/or sodium hydroxide,
NF are used to adjust the pHto 7.
The recombinant protein in Follistim® AQ has been standardized for FSH in
vivo bioactivity in terms of the First International Reference Preparation
for human menopausal gonadotropins (code 70/45), issued by the World Health
Organization Expert Committee on Biological Standardization (1982). Under current
storage conditions, Follistim® AQ may contain up to 11% of oxidized follitropin
beta.
In clinical trials with Follistim®, serum antibodies to FSH or anti-CHO
cell derived proteins were not detected in any of the treated patients after
exposure to Follistim®for up to three cycles.
Therapeutic Class: Infertility.
REFERENCES
1As determined by the Ph. Eur. test for FSH in
vivo bioactivity and on the basis of the molar extinction coefficient at
277 nm (ε s:mg-1cm-1) = 1.066.Last reviewed on RxList: 11/17/2008




Follistim AQ Drug Description
Follistim® AQ
(follitropin beta) Injection
FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ »




Follistim® AQ (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results ina highly purified preparation with a consistent
hFSH isoform profile and high specific activity1. The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.
The amino acid sequence and tertiary structure of the product are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physio-chemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ is presented as a sterile aqueous solution intended for SUBCUTANEOUS
or INTRAMUSCULAR administration. Each single-use vial of Follistim® AQ contains
the following per 0.5 mL: 75 IU or 150 IU of FSH activity; 25 mg sucrose, NF;
7.35 mg sodium citrate (dihydrate), USP; 0.25 mg L-methionine, USP; 0.1 mg polysorbate
20, NF; and water for injection, USP. Hydrochloric acid, NF and/or sodium hydroxide,
NF are used to adjust the pHto 7.
The recombinant protein in Follistim® AQ has been standardized for FSH in
vivo bioactivity in terms of the First International Reference Preparation
for human menopausal gonadotropins (code 70/45), issued by the World Health
Organization Expert Committee on Biological Standardization (1982). Under current
storage conditions, Follistim® AQ may contain up to 11% of oxidized follitropin
beta.
In clinical trials with Follistim®, serum antibodies to FSH or anti-CHO
cell derived proteins were not detected in any of the treated patients after
exposure to Follistim®for up to three cycles.
Therapeutic Class: Infertility.
REFERENCES
1As determined by the Ph. Eur. test for FSH in
vivo bioactivity and on the basis of the molar extinction coefficient at
277 nm (ε s:mg-1cm-1) = 1.066.Last reviewed on RxList: 11/17/2008




Follistim AQ Drug Description
Follistim® AQ
(follitropin beta) Injection
FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ »




Follistim® AQ (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results ina highly purified preparation with a consistent
hFSH isoform profile and high specific activity1. The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.
The amino acid sequence and tertiary structure of the product are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physio-chemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ is presented as a sterile aqueous solution intended for SUBCUTANEOUS
or INTRAMUSCULAR administration. Each single-use vial of Follistim® AQ contains
the following per 0.5 mL: 75 IU or 150 IU of FSH activity; 25 mg sucrose, NF;
7.35 mg sodium citrate (dihydrate), USP; 0.25 mg L-methionine, USP; 0.1 mg polysorbate
20, NF; and water for injection, USP. Hydrochloric acid, NF and/or sodium hydroxide,
NF are used to adjust the pHto 7.
The recombinant protein in Follistim® AQ has been standardized for FSH in
vivo bioactivity in terms of the First International Reference Preparation
for human menopausal gonadotropins (code 70/45), issued by the World Health
Organization Expert Committee on Biological Standardization (1982). Under current
storage conditions, Follistim® AQ may contain up to 11% of oxidized follitropin
beta.
In clinical trials with Follistim®, serum antibodies to FSH or anti-CHO
cell derived proteins were not detected in any of the treated patients after
exposure to Follistim®for up to three cycles.
Therapeutic Class: Infertility.
REFERENCES
1As determined by the Ph. Eur. test for FSH in
vivo bioactivity and on the basis of the molar extinction coefficient at
277 nm (ε s:mg-1cm-1) = 1.066.Last reviewed on RxList: 11/17/2008




Follistim AQ Drug Description
Follistim® AQ
(follitropin beta) Injection
FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ »




Follistim® AQ (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results ina highly purified preparation with a consistent
hFSH isoform profile and high specific activity1. The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.
The amino acid sequence and tertiary structure of the product are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physio-chemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ is presented as a sterile aqueous solution intended for SUBCUTANEOUS
or INTRAMUSCULAR administration. Each single-use vial of Follistim® AQ contains
the following per 0.5 mL: 75 IU or 150 IU of FSH activity; 25 mg sucrose, NF;
7.35 mg sodium citrate (dihydrate), USP; 0.25 mg L-methionine, USP; 0.1 mg polysorbate
20, NF; and water for injection, USP. Hydrochloric acid, NF and/or sodium hydroxide,
NF are used to adjust the pHto 7.
The recombinant protein in Follistim® AQ has been standardized for FSH in
vivo bioactivity in terms of the First International Reference Preparation
for human menopausal gonadotropins (code 70/45), issued by the World Health
Organization Expert Committee on Biological Standardization (1982). Under current
storage conditions, Follistim® AQ may contain up to 11% of oxidized follitropin
beta.
In clinical trials with Follistim®, serum antibodies to FSH or anti-CHO
cell derived proteins were not detected in any of the treated patients after
exposure to Follistim®for up to three cycles.
Therapeutic Class: Infertility.
REFERENCES
1As determined by the Ph. Eur. test for FSH in
vivo bioactivity and on the basis of the molar extinction coefficient at
277 nm (ε s:mg-1cm-1) = 1.066.Last reviewed on RxList: 11/17/2008




Follistim AQ Drug Description
Follistim® AQ
(follitropin beta) Injection
FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ »




Follistim® AQ (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results ina highly purified preparation with a consistent
hFSH isoform profile and high specific activity1. The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.
The amino acid sequence and tertiary structure of the product are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physio-chemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ is presented as a sterile aqueous solution intended for SUBCUTANEOUS
or INTRAMUSCULAR administration. Each single-use vial of Follistim® AQ contains
the following per 0.5 mL: 75 IU or 150 IU of FSH activity; 25 mg sucrose, NF;
7.35 mg sodium citrate (dihydrate), USP; 0.25 mg L-methionine, USP; 0.1 mg polysorbate
20, NF; and water for injection, USP. Hydrochloric acid, NF and/or sodium hydroxide,
NF are used to adjust the pHto 7.
The recombinant protein in Follistim® AQ has been standardized for FSH in
vivo bioactivity in terms of the First International Reference Preparation
for human menopausal gonadotropins (code 70/45), issued by the World Health
Organization Expert Committee on Biological Standardization (1982). Under current
storage conditions, Follistim® AQ may contain up to 11% of oxidized follitropin
beta.
In clinical trials with Follistim®, serum antibodies to FSH or anti-CHO
cell derived proteins were not detected in any of the treated patients after
exposure to Follistim®for up to three cycles.
Therapeutic Class: Infertility.
REFERENCES
1As determined by the Ph. Eur. test for FSH in
vivo bioactivity and on the basis of the molar extinction coefficient at
277 nm (ε s:mg-1cm-1) = 1.066.Last reviewed on RxList: 11/17/2008





Other reviews about Follitropin Beta on wordpress

THE FUTURE WHERE IT IS DIVIDED
  by Mark
.. Ûž Unexpectedly, in future IMT to include only individuals with U.S.-born parents and grandparents), three types of peroxisome proliferator-activated receptors (PPAR), artificial photonic devices suggests that the […]


Progeny At What Price?
  by eheavenlygads
Allow me to begin here by thanking my favorite blogger, Jane, for tipping me off to the recent births of two sets of sextuplets in Arizona and Minnesota.  […]


Injectables!!! BAM!!!
  by brown-eyed-girl
That’s right folks, we’re gonna kick it up a notch and skip the second round of Clomid and move right on over to injectables!  That’s basically what happened […]


Follistim Pen Injections
  by babystuess
I've now had all 3 of my Follistim shots.  Alex & I decided that we would administer the shots at 6:30 pm each night.  On Friday night, we […]


Merck - Schering-Plough
  by El Horror
About - Schering-Plough = Merger of Schering Corporation and Plough Inc. in 1971. - 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%). 41.1 billion dollar deal by […]


Day 2
  by Yen Ee
Alrighty then. Day 2 of my period = first jab of follitropin beta.



Other reviews about Follitropin Beta on web:

Mayo Clinic offers award-winning medical and health information and tools for healthy living. Follitropin Beta (Subcutaneous Route) - MayoClinic.com


All about Follitropin Beta. View complete and up to date Follitropin Beta information - part of the Drugs.com trusted medication database. Follitropin Beta Facts and Comparisons at Drugs.com


Consumer information about the medication FOLLITROPIN BETA - INJECTION (Follistim), includes side effects, drug interactions, recommended dosages, and storage information. FOLLITROPIN BETA - INJECTION (Follistim) side effects, medical ...


follitropin beta Subcutaneous patient information. Detailed drug information for the consumer, includes dosage, follitropin beta Subcutaneous side effects and more. follitropin beta Subcutaneous consumer information from Drugs.com


Resource URI: http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00066 Follitropin beta | D2R Server publishing the DrugBank Database


Learn about the prescription medication Follistim AQ (Follitropin Beta), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Follistim AQ (Follitropin Beta) Drug Information: Uses, Side ...


Follistim® AQ Cartridge (follitropin beta injection)... ... How Follistim® AQ Cartridge Works; Recombinant DNA Technology; Frequently Asked Questions 00 Follistim AQ Cartridge


Follitropin Beta is a hormone used to treat fertility problems. It is used in combination with another hormone hCG to stimulate the ovaries in women or used alone to stimulate ... Follistim 300 IU AQ Cartridge (Follitropin Beta)


Branded as Follistim® in the United States and as Puregon® throughout the rest of the world by Organon. Follitropin Beta is a gonadotrophin hormone and consists of highly purified ... Follistim 600 IU AQ Cartridge (Follitropin Beta)


Follitropin-beta.kz is a domain controlled by three name servers at organon.com. All three of them are on different IP networks. The primary name server is ns1.organon.com ... follitropin-beta.kz





Featured Reviews

Reviews Mycobutin

Mycobutin Drug Description Mycobutin® (rifabutin) Capsules, USP DRUG DESCRIPTION What are the possible side effects of rifabutin (Mycobutin)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Enalapril

Vasotec Drug Description VASOTEC® (enalapril maleate) USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is...
Read More  |  Review This
Reviews Levetiracetam Extended-Release Tablets

Keppra XR Drug Description KEPPRA XR (levetiracetam) Extended-Release Tablets DRUG DESCRIPTION What are the possible side effects of levetiracetam (Keppra, Keppra XR)? Get emergency medical help if you have any of these signs of...
Read More  |  Review This
Reviews Norethindrone and Ethinyl Estradiol Tablets

Femcon Fe Drug Description FEMCON® Fe (norethindrone and ethinyl estradiol) Tablets, Chewable and Ferrous Fumarate Tablets 0.4mg/35mcg Ferrous fumarate tablets are not USP for dissolution and assay. Patients should be counseled that...
Read More  |  Review This
Reviews Hydrocodone Bitrate and Acetaminophen Tablets

Vicodin HP Drug Description Vicodin HP® (hydrocodone bitartrate and acetaminophen) 10 mg/660 mg tablets, USP DRUG DESCRIPTION Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration. Hydrocodone...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....